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Abstract 
 
        Cancer is the second leading cause of death worldwide. Conventional therapies 
cause serious side effects and, at best, merely extend the patient’s lifespan by a few 
years. Cancer control may therefore benefit from the potential that resides in 
alternative therapies. There is thus an increasing demand to utilize alternative concepts 
or approaches to the prevention of cancer. The principal aim of this research is to 
screen and identify new synthetic compounds “chromenes”, with high efficiency, for 
breast cancer therapy. In this study, we have screened four newly designed and 
synthesized chromenes (C1, C15, C28 and C29) for their potential anticancer activities 
against the highly aggressive and invasive triple negative breast cancer (TNBC) cells. 
We found that three (C1, C15 and C28) of the four tested chromenes exhibited a strong 
anti-proliferative activity against the MDA-MB-231 cells. Moreover, we found that 
chromenes exerts their anti-breast cancer effect through induction (i) of cell cycle 
arrest at the M phase confirmed by an increased expression of the M phase specific 
marker, p(ser10)H3 and (ii) activation of the apoptotic cell death program, revealed by 
increased levels of cleaved PARP , a marker of apoptosis. Further investigations are 
underway to elucidate the molecular mechanism(s) through which chrome exerts their 
effects. In conclusion, our current study provide preliminary evidences that chromenes 
could be a potential therapeutic compounds against the TNBC. 
Keywords: Cancer, Chromenes, anti-cancer agent, apoptosis, cell viability, and cell 
cycle. 
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 )cibarA ni( tcartsbA dna eltiT
 
 فرز مواد كيميائيه مصنعه من ( كرومين) ذات فعاليه مضاده للسرطان
 صالملخ
 لتقليديةاالسرطان هو السبب الرئيسي ويصنف في المستوي الثاني لسبب الوفيات في العالم. العلاجات         
نوات. ستتسبب في أثار جانبيه خطيره, وفي احسن الظروف فهي تعمل علي مجرد اطاله عمر المريض الي بضع 
يدا علي . وعليه هناك طلبا متزاالبديلةمن الامكانات التي تتواجد في العلاجات  الاستفادةولمكافحه السرطان علينا 
ديد هو فحص وتح الدراسةمن السرطان.  الهدف الرئيسي من هذه  الوقايةفي  المسالمةو  البديلةاستخدام العلاجات 
 لعلاج السرطان . السميةو منخفضه  عالية كفاءةب" senemorhc" الجديدة الصناعيةالمركبات 
، 1Cوتوليفها (  "senemorhc"مركبات لقمنا بترتيب أربعة  لعلاج سرطان الثدي في هذه الدراسة,      
ضد سرطان الثدي و خصيصا حديثا للأنشطة المضادة للسرطان المحتملة  و التي صممت )92Cو 82C، 51C
 .شديدة العدوانية والغازيةالثلاثية اليا خلاالذي يعرف بال) CBNTالسلبي (
" ذات مفعول قوي ومؤثر ضد senemorhc"ل المختارة الأربعةفي دراستنا وجدنا ان ثلاث مركبات من بين 
يقوم على محاربة مرض سرطان  "senemorhc"تأثير وعلاوة على ذلك، وجدنا أن خلايا سرطان الثدي. 
 ,Mللمرحلة  علامه معينه زيادةوهذا ما اكده  Mخلية في المرحلة دورة ال ووقف اعتقال(أ) الثدي من خلال
و الذي  المشقوق PRAPالتي كشفت عنها زيادة مستويات  و تفعيل برنامج موت الخلية(ب) و  P)3H )01res(
جارية لتوضيح الآلية الجزيئية المزيد من الدراسات و التحقيقات هنالك الموت الخلايا المبرمج.  الى يرمز
و الذي  "senemorhc" التي لدينا توفر الأدلة الأولية ل . في الختام، الدراسة الحاليةsenemorhc"" بركمل
  CBNT".المركب العلاجي المحتمل ضد " كونيمكن أن ي
 
السرطان, كرومينس, مواد ضد السرطان, موت الخلايا المبرمج, حيويه الخلايا, دوره  مفاهيم البحث الرئيسيه:
 .الحياه الخلويه
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Chapter 1: Introduction 
 
1.0 Literature review 
1.1 Cancer  
        Cancer is defined as an abnormal growth of the cells. These cells acquire defects 
in differentiation and in the mechanisms that control cell cycle and/or induce apoptosis 
in response to various stresses or DNA damage [1]. Aberrations in gene expression 
patterns lie at the heart of tumorigenesis. Such defects increase the ability of cancer 
cells to survive, grow, and divide in their original tissue and then to metastasize, which 
requires survival and proliferation in other environments [2,3]. The development of 
cancer generally requires many steps, each governed by multiple factors, some 
dependent on the genetic constitution of the individuals, others dependent on his or her 
environment and way of life [4]. Unfortunately, different cancers have different 
environmental risk factors, and a population that escapes one such danger is usually 
exposed to another.  
 
1.1.1 Incidence of Cancer 
        Cancer is a major public health problem with 8.2 million deaths from cancer in 
the world in 2012. (WHO, 2012). In UAE, 1202 cancer cases were registered in 2007. 
Moreover, many studies estimated that the world population will reach 7.5 billion in 
2020 and 15 million of which will be diagnosed with cancer, while 12 million people 
will die from cancer [4,5]. Cancer incidence and mortality has increased dramatically 
in both developed and developing nations. In UAE, cancer is the third leading cause 
of death following cardiovascular diseases and accidents.   
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1.1.2 Breast Cancer  
 
        Breast cancer is the most common threats in women, and the second leading cause 
of death following lung cancer [6]. An estimated diagnosed new cases of breast cancer 
reach 1.38 million per year with 458000 deaths from breast cancer worldwide [7]. 
They classified the breast cancer routinely according to stage, pathology, grade and 
expression of estrogen receptor (ER), progesterone receptor (PR) or human epidermal 
growth factor receptor (Her2/neu). Approximately 15% of globally diagnosed breast 
cancer are of the highly aggressive and invasive triple-negative (TNBC) which is 
defined by the absence of these targets (ER-,PR- and Her2/neu – negative) [8] . 
 
1.1.3 Global Burden of Breast Cancer 
        Women are at increasingly high risk of breast cancer, due to changing exposures 
to reproductive and lifestyle characteristics overtime, making breast cancer a major 
health problem worldwide, with incidence rates increasing in most countries in the past 
few decades. Breast cancer risk has historically been low in developed countries 
compared to what is observed in the developing countries. There are several factors 
with this increase and is widely attributed to the ‘‘westernization’’ of lifestyles, an ill-
defined surrogate for changes in factors such as childbearing, anthropometric 
attributes, and lifestyle characteristics. A dramatic reductions in breast cancer 
mortality rates in developed countries have been noticed following the introduction of 
screening and substantial improvements in treatment [9].  
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1.1.4 Causes of Breast Cancer 
         In general, there are many risk factors cause the breast cancer. For example, 
menstrual and reproductive risk factors, radiation factors, lifestyle risk factors which 
include body size, physical activity, smoking, alcohol and diet. Genetics, personal, and 
family history of breast disease is another factor which play a role in breast cancer [9]  
1.1.5 Hallmarks of Cancer 
       Unlike normal cells, a mutation in the tumor suppressor gene P53, makes cancer 
cells more capable of evading the process of programmed cell death "apoptosis". To 
maintain nutrient supply, tumor cells induce the formation of new blood vessels 
through the process called "angiogenesis". In advance stage of tumorgenesis, the 
processes of "migration" and "invasion" happen when cancer cells detach from their 
tissues and migrate to invade other tissues and cause damage. According to that, the 
"primary tumor" can colonize in another organ and form a "secondary tumor" in a 
process termed "metastasis" [10]. Understanding the molecular pathways of cell 
division and apoptosis is essential to investigate approaches through which cancer 
develops. It is also critical in the process of generation of anticancer treatment. 
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Figure 1 Hallmarks of Cancer. 
   
1.2 Cell Cycle 
       Cell cycle is a process of duplication and division where cells reproduces by 
performing an orderly sequence of events in which it duplicates its contents and then 
divides in two. Cell cycle has a control system which regulate cell numbers in the 
tissues of the body. When the system malfunctions, excessive cell divisions can results 
in cancer [11]. 
 
1.2.1 The Phases of Cell Cycle 
      Duplication of DNA in the chromosomes and then segregation of the copies into 
two genetically identical daughter cells is the basic function of the cell cycle. Cell cycle 
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is controlled by two major phases. In S phase (DNA synthesis), chromosome 
duplication occurs and occupies about half of the cell-cycle time in a typical 
mammalian cell. After that, chromosome segregation and cell division occur in M 
phase (mitosis) and requires much less time. Two major events comprises in M phase, 
Nuclear division (mitosis) during which the copied chromosomes are distributed into 
a pair of daughter nuclei and cytoplasmic division (cytokinesis), which the cell itself 
divides in two [12, 13].  
           Most cell cycles have extra gap phases to allow more time for growth. G1 phase 
between M phase and S phase and G2 phase between S phase and M phase. G1, S, and 
G2 together are called "interphase" (figure 2). The two gap phases provide time for the 
cell to monitor the internal and external environment to ensure that conditions are 
suitable and preparations are complete before the cell commits itself to the major S 
and M phases [14].  
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Figure 2 Normal cell cycle phases 
 
1.2.2 Cell Cycle Control System 
       The cell-cycle control system is based on a connected series of biochemical 
switches, each of which initiates a specific cell-cycle event. In most eukaryotic cells, 
the cell-cycle control system triggers cell-cycle progression at three major regulatory 
transitions or checkpoints (figure2). The first checkpoint in late G1 where the cells 
enter cell cycle and proceed to S phase. The second is the G2/M checkpoint before the 
cell enter to M phase to make sure all DNA replicated and the environment is favorable 
for replication. The third is the metaphase-to-anaphase transition, where the control 
system stimulates sister-chromatid separation, leading to the completion of mitosis and 
cytokinesis. Any problems detected inside or outside the cell, will block the 
progression through each of these checkpoint by the control system of cyclins and 
cyclin-dependent kinases [10,15,16,17]. 
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1.2.3 The role of Cyclin-Dependent Protein Kinases (CDKs) 
       A family of protein kinases known as cyclin-dependent kinases (CDKs) are the 
central components of the cell-cycle control system. Any cyclical changes in the 
phosphorylation of intracellular proteins that initiate or regulate the major events of 
the cell cycle are depend on the activities of these kinases as the cell progresses through 
the cycle [15] . The most important proteins that regulate these kinases are cyclins. 
Cyclins were originally named because they undergo a cycle of synthesis and 
degradation in each cell cycle. The activation of cyclin-CDK complexes that result 
from cyclical degradation of cyclins trigger cell-cycle events. Thus, activation of S-
phase cyclin-Cdk complexes (S-CDK) initiate S phase, while activation of M-phase 
cyclin-Cdk complex (M-CDK) triggers mitosis. The mechanisms that control the 
activities of cyclin-Cdk complexes include phosphorylation of the CDK subunit, 
binding of CDK inhibitor proteins (CKIs), proteolysis of cyclins, and changes in the 
transcription of genes encoding CDK regulators. Two additional enzyme complexes 
play a role in the cell-cycle control system, the Anaphase promoting complex (APC/C) 
and SCF ubiquitin ligases, which catalyze the ubiquitylation and consequent 
destruction of specific regulatory proteins that control critical events in the cycle 
[18,19] . 
1.2.4 Disrupted CDK Activating Enzyme and CDK Inhibitors 
        Progression of the cell cycle from one phase to another is allowed by CDKs and 
cyclins complexes. The activation of CDKs is controlled by the Cdc25 enzymes 
through dephosphorylation, which allow the transition from one phase to another. 
There are three members of Cdc25, the Cdc25A, Cdc25B and Cdc25C. the Cdc25A is 
mandatory for G1/S transition, while the Cdc25B is required for S phase and Cdc25C 
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mediate transition to M phase through the activation of CDK1-cyclin B. Therefore, 
mutation in the expression of such proteins lead to dysregulation in the cell cycle 
progression and can promote tumergenesis [20]. 
       The other regulatory mechanism for CDK activity involves CDK inhibitor 
proteins (CKIs). CKIs are capable of exerting inhibition on cyclin-CDK complexes. 
There are two major families of CKI proteins, the Inhibitor Kinase 4 (INK4) family 
and the CDK interacting protein/Kinase inhibitory protein (CIP/KIP) family. The 
INK4 inhibitors consists of p15(INK4b), p16(INK4a), p18(INK4c) and p19(INK4d), 
while the CIP/KIP family consist of CIP1 (p21), KIP1 (p27), and KIP2 (p57),which 
can associate with CDK enzymes and prevent cyclin binding [15] . The activation of 
these inhibitory proteins is controlled by either internal or external inducers. For 
instance, p21 is a downstream target for the tumor suppressor transcription factor 
protein p53. Whereas, the activation of p15 and p27 is controlled by the Transforming 
Growth Factor Beta (TGF-B) proteins of the surrounding cellular environment [21]. 
Mutation in these inhibitors can lead to cancer. For example, mutations in CKIs such 
as INK4 and p21 are capable of promoting tumorgenesis and found mutated in 
aggressive types of cancer such as breast and lung cancers [18]. 
 
1.3 Apoptosis 
        Cells that are irreversibly damaged, no longer needed, or are a threat to the 
organism can be eliminated quickly and neatly by a process called programmed cell 
death or apoptosis [11]. 
9 
 
 
 
 
       Apoptosis depends on proteolytic enzymes called caspases, which cleave specific 
intracellular proteins to help kill the cell. One of these intracellular proteins is Poly 
(ADP-Ribose) Polymerase (PARP) which help in DNA repair and cell proliferation 
and serves as an apoptosis marker once it is cleaved into two large and small subunits 
by a caspases. Caspases present as inactive precursors called procaspases. Once 
activated, they cleave and activate downstream executioner procaspases, which 
activate other executioner procaspases, producing an amplifying, irreversible 
proteolytic cascade [10, 22].  
       There are two distinct pathways that control the activity of procaspases and 
leading to apoptosis. The extrinsic pathway is activated by extracellular ligands that 
bind to cell-surface death receptor. The death receptors recruit procaspases-8 and 10 
via adaptor proteins to form the Death-inducing signaling complex  (DISC). The 
intrinsic pathway is activated by intracellular signals generated when cells are stressed. 
In this pathway, cytochrome C that is released from the intermembrane space of 
mitochondria activates Apoptosis protease activating factor 1 (Apaf1). The Apaf1 
proteins assemble into apoptosome and recruit and activate procaspase-9. Both anti-
apoptotic and pro-apoptotic Bcl2 proteins regulate the intrinsic pathway by controlling 
the release of mitochondrial intermembrane proteins, while Inhibitor of apoptosis 
proteins (IAPs) inhibit activated caspases and promote their degradation [23,24,25]. 
        The ability of cancer cells to evade programmed cell death leads to 
carcinogenesis[10] . This is achieved mainly through three stages of dysfunctionality 
in the pathway of apoptosis, which involve loss of balance between pro-apoptotic and 
anti-apoptotic proteins, impairment in cell death receptors and decreased caspase 
activity[26]. 
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       Disruption in apoptosis pathway is also linked to mutation in P53. For instance, 
down regulation of mutant P53 has been reported to have a major effect on reducing 
the formation of colonies in cancer cells and enhancing apoptosis [27].  
     The morphological changes in an apoptotic cells summarized in any alterations in 
nucleus, cell membrane and in cellular organelles. Moreover, apoptotic cells acquire a 
structure of rounded cells [28].    
 
1.4 Treatment  
       Cancer is treated with radiation, surgery, and chemotherapy. However, these 
currently used clinical therapies showed limitations and high morbidity and mortality 
rates. Therefore, there is an urgent need for the development of new therapeutic drugs 
that will be more efficient, with less side effects or to be used in combination of 
existing ones. 
      The ultimate goal of all anticancer treatments is to selectively eradicate tumor cells, 
and the favored mechanism for this is apoptosis . A drawback of this strategy is that 
tumor cells frequently develop drug-resistant phenotypes by accumulating alterations 
in key regulators of the apoptotic pathway. The drug-resistant phenotype is often 
responsible for tumor regrowth and treatment failure [29]. 
       Since microtubules play a critical role in mitosis by creating the mitotic spindle, 
tubulin has long been a natural target for chemotherapeutics. The major classes of 
microtubule-interacting agents are Taxanes and vinca and Colchicine site binders. 
Over expression of β-tubulin isotypes results in decreasing drug accumulation within 
the cancer cell due to the ability of pumping out anticancer drugs [30]. Identification 
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of new anti-cancer drugs that trigger cell death by acting on alternative pathways, or 
on different levels of a given pathway, can overcome resistance to chemotherapy. 
Furthermore, the availability of a broad range of anticancer drugs allows choosing 
between individual treatments to reduce toxicity [31,32].  Recent developments of 
molecular cancer therapeutics have produced new drugs that show promising 
antitumor effects in vivo [31].  
 
1.4.1 Chromenes  
         Chromenes are a polycyclic organic compound that results from the fusion of a 
benzene ring to a heterocyclic pyran ring. These compounds play a role as a potential 
anticancer agent that can activate or promote apoptosis in cancer cell. Cai,S.X et al 
studied the effect of chromenes in T47D cells and they proved that 4H-Chromenes 
were identified as potent apoptosis inducers through inducing nuclear fragmentation 
and arrest cells at the G2/M stage followed by apoptosis in multiple human cell lines. 
4H-Chromenes are developed as chemotherapeutic agents that target the colchicine 
binding site and serve as inhibitor for tubulin polymerization and cytotoxic against 
human cancer cells. For that, chromenes compound could be further developed as a 
potential therapeutic agent for a variety of aggressive cancers [33,34, 35]  . 
 
  
12 
 
 
 
 
1.5 Objectives 
         The objectives of this study are to screen for new synthetic chromenes for their 
antiproliferative and proapoptotic effect on triple negative MDA-MB-231 breast 
cancer cell line and to study the mechanism(s) of action of these compounds on cancer 
cells. 
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Chapter 2: Materials and Methods 
 
2.1 Cell Culture  
        Human cancer cell line of breast origin MDA-MB-231 was maintained in 
appropriate cell culture medium DMEM (Hyclone, Cramlington, UK) completed with 
10% fetal bovine serum and 2% antibiotic (FBS) (Hyclone, Cramlington, UK). Cells 
was maintained in a humidified incubator at 37oC in a 5% CO2 atmosphere. 
2.2 Chemical Compounds 
       Chromene compounds were synthesized by Dr Soleiman Hisaindee from the 
department of Chemistry, UAE University. These chemical compounds were 
suspended in DMSO at a concentration of 200 µM and stored at -80 oC .  
 
Figure 3 Chromenes compounds’ structures 
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2.3 Cell Viability 
        Cancer cells were seeded in triplicate in 96-well plates at a density of 5,000 cells 
/ well. After 24 h, cells were treated with or without various concentrations of 
Chromene compounds for different durations. Control cells were treated with vehicle  
(DMSO). The effect of drugs on cell viability was determined using Cell Cytotoxicity 
Kit (Abcam) according to the manufacturer’s specifications. The data was presented 
as proportional viability (%) by comparing the treated group with the untreated cells, 
the viability of which is assumed to be 100%.  
2.4 Analysis of Morphology 
         MDA-MB-231 cells treated with C15 with different concentrations were 
examined for morphological changes using EVOS Biotechnology inverted microscope 
which is equipped with an indigenous camera and pictures were taken with 40X and 
400X magnification. 
2.5  Western Blot  
        Cells were seeded with 1.5 million of cells in 100mm dishes and cultured for 24h 
with or without the addition of C15. Cells were then washed twice with ice-cold PBS, 
scraped and lysed in RIPA buffer. The lysates were centrifuged at 13000 rpm for 30 
min at 4ºC after incubation for 30 min in ice. Protein concentration of lysate was 
determined by using BCA kit. The total cell lysate were separated via SDS-PAGE and 
transferred onto a nitrocellulose membrane. Then, blocked for 1 h at room temperature 
with 5% non-fat dried milk in PBST (phosphate buffer saline with 0.05% Tween 20). 
Overnight incubation with specific primary antibodies was performed  in at 4ºC. 
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Horseradish peroxidase-conjugated anti-IgG was used as secondary antibody. The 
membranes were then exposed to X-ray film. 
2.6  Flow Cytomertic Analysis of Cell Cycle Distribution 
      Cancer cells were seeded with 300,000 cells in 60mm culture dishes and cultured 
for 24 h before addition of various concentrations of C15 compound or equal volume 
of vehicle (DMSO) as control. After incubation for the indicated time, cells were 
harvested by trypsin release, washed twice with ice-cold PBS, resuspended in PBS, 
fixed with an equal volume of 100% ethanol and incubated for at least 12h at -220C. 
Before flow cytometry analysis, cells were pelleted, washed twice with PBS. Then  
Stained with cell cycle kit (Millipore) and analyzed with MUSE cell analyzer.  
Percentage of cells in G1, S and G2/M phases was determined using the FlowJo 
software. 
2.7  Statistical Analysis 
The statistical analysis were done using SPSS version 21. Data were reported as 
group mean ± SEM. A student's t-test for paired or unpaired values was performed. 
Significance for all statistical comparisons was set at p value of <0.05 using a two-
tailed test. 
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Chapter 3: Results 
 
3.1  Effect of the Chromenes on the Cellular Viability of the MDA-MB-231 Breast 
Cancer Cell Line. 
       To examine the anticancer effect of chromenes on breast cancer cell line, we first 
measured the effect of various concentration of chromenes (C1, C15, C28 and C29) 
on the proliferation of MDA-MB-231 cell line. Our results showed a nice decrease in 
the cellular viability of MDA-MB-231 cell line when exposed to various concentration 
of Chromenes (C1, C15 and C28) but not with C29. Furthermore, treatment with 2.5 
µM of chromenes 1, 15 and 28 for 24 (Figure 4A) and 48 Hrs (Figure 4B) resulted in 
approximately 50% decrease in the cell viability of MDA-MB-231 cell line. The 
exposure of MDA-MB-231 to chromenes decreased cellular viability in a 
concentration and time-dependent manner compared to a control cells treated with 
vehicle (ethanol).  
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Figure 4 Inhibition of cellular viability of MDA-MB-231 cells by 
Chromenes in concentration and time dependent manner. MDA-MB-231 
cells were treated with and without the indicated concentration of 
chromenes (1, 15, 28, and 29) for 24hrs (A) and 48hrs (B). viability 
monitored as described in materials and methods. Data represent the 
mean of four independent experiments carried out in triplicate. 
Statistical analysis for cell viability data was performed and reported as 
a group of ±SEM. p value of <0.05 was considered statistically 
significant. 
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3.2 Morphological Changes Induced by Chromene 15 in MDA-MB-231 Cell Line. 
        Next, we focused our attention to C15 only. To understand the mechanism(s) of 
action of this compound (C15)  in inhibiting the cellular viability, we first looked at 
the morphology of MDA-MB-231 in control and C15-treated cells for 24 hours. As it 
is shown in figure 5, light microscopy observation revealed that the number of MDA-
MB-231 cells in the presence of C15 significantly decreased compared to the control. 
Morphological observation also revealed that treated cells exhibited a rounded-shaped 
and smaller size a characteristic of apoptotic cells (Figure 5).  
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Figure 5 Morphological changes in MDA-MB-231 cells treated with C15 for 24 
hrs.  Images taken at 40x and 400x magnifications. Cells were examined under 
EVOS XL Core Cell Imaging System (Life Technologies). 
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3.3 Significant Induction Of Apoptosis By C15 In Mda-Mb-231 Cells. 
         Further investigation of the mechanism of cell death induced by  C15 on MDA-
MB-231 cells, we studied the expression of cleaved PARP in treated cells with 
different concentrations of C15 for 24hrs. As shown in figure 6, a high accumulation 
of cleaved PARP  which is considered as an apoptosis marker was observed, and thus  
suggesting the occurrence of apoptosis in C15-treated MDA-MB-231 cells. 
 
Figure 6 Induction of apoptosis by C15 in MDA-MB-231 cells. Cells were treated for 
24 hrs with different concentrations of the C15. Western blot analysis was carried out 
using anti-cleaved PARP antibody. 
 
3.4 C15 Leads To Mitotic Arrest on Mda-Mb-231 Cell Line 
        The ability of an anticancer drug to affect cell cycle distribution can provide 
information regarding its cytotoxic mechanism(s) of action. Therefore, we investigated 
the effect of C15 on cell cycle distribution.  To achieve this, cells were treated with 
increasing concentrations of C15 for 24 hrs and then cell cycle phases were measured. 
At the concentration of 2.5 µM, C15 caused an obvious G2/M arrest as it is shown in 
figure 7. Indeed the population of G2/M increased significantly, from 30 to over 60%, 
as the concentration of C15 increased indicating that C15-treated MDA-MB-231 cells 
underwent  cell cycle arrest at G2/M phase.  
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G1 
G2/
G2/M 
Figure 7 Induction of G2/M cell cycle arrest by C15 in MDA-MB-231 cell line. Cells 
were exposed to various concentrations of C15 for 24h. After treatment cell analyzed 
for cell cycle distribution using flow cytometry. Data are reprentative of three 
independent experiments. Percentage of cells in G1, S and G2/M phases was 
determined using the FlowJo software. p value of <0.05 was considered statistically 
significant. 
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3.5 C15 Leads To Upregulation Of P21 Expression In Mda-Mb-231 Cells 
        It is well known that the  cyclin dependent kinase (CDK) inhibitor p21 cause a 
cell cycle arrest when cells are exposed to anticancer compounds [15]. Because we 
found that C15 induces cell cycle arrest at G2/M phase in C15-treated cells, we decided 
to examine the level of p21, by Western Blot,  in response to C15. As shown in figure 
8, the expression of p21 increased in MDA-MB-231 cell treated with low 
concentrations (1 and 5 µM) of C15. Interestingly a higher  concentration of  C15 (10 
µM)  did not show a change in p21 level. Still we cannot rule out the possibility that 
p21 increased at early time point but due to massive cell death at high concentration, 
the protein undergoes degradation. From this result we can  conclude that C15 induce 
cell cycle arrest through induction of the CDK inhibitor, p21. 
 
Figure 8 Expression of p21 in C15-treated MDA-MB-231 cells. Cells were treated 
with various concentrations of C15 or vehicle as a control for 24 h and the expression 
of p21 was estimated by Western Blot. 
 
3.6 Phosphorylation Status of H3 (Ser 10) Detected In C15-Treated Mda-Mb-231 
Cells  
        To determine whether C15 induce cell cycle arrest specifically at mitosis or G2 
phase, we analyzed the expression  of G2 and M phase specific markers, cyclin B and  
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histone H3-phospho (Ser 10), respectively by Western Blot. Figure 9 showed that the 
level of C15- treated cells significantly increase the phosphorylation level of H3-
phospho (Ser 10)  in dose-dependent manner in response to C15. The level of cyclin 
B1 on the other hand remained unaffected (Figure 9). Altogether, our results indicates 
that C15 induces a specific cell cycle arrest at the M phase.  
 
Figure 9  Expression of cell cycle regulator in C15-treated MDA-MB-231.Western 
blot analysis of phosphor (ser10)-H3 and cyclin B1 in MDA-MB-231 cells exposed 
for 24 h with ethanol or indicated concentrations of C15. 
                 
3.7 Effect Of C15 In The Dna Damage Of Mda-Mb-231 Cells 
       Finally, we tested whether C15 mediates its effect through induction of DNA 
damage as it is the case for  numerous ancticancer compounds. Toward this, we 
examined the level of the marker of DNA damage ɣ-H2AX  in treated-cells by Western 
Blot. As it is shown in figure 10, C15 did not induce any significant increase on the 
level of ɣ-H2AX, thus indicated that C15 mediated effect is independent of DNA 
damage.  
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Figure 10 Effect of C15 in the DNA damage of MDA-MB-231 cells. C15 did not cause 
a DNA damage in MDA-MB-231 cells. western blot analysis of phospo-H2AX in 
MDA-MB-231 cells exposed for 24 h with indicated concentrations of C15 or vehicle 
as a control. 
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Chapter 4: Discussion 
 
      The main goal of anticancer drugs is to inhibit cell cycle progression and induce 
cell death. Many natural products play a role in these two events and act as anticancer 
drugs in the field of cancer treatment. Hence, we started our investigation for potential 
anticancer effect of C15 by testing its cytotoxicity effect and its ability to induce cell 
death in MDA-MB-231 cell line.  
       In our study, we have shown that chromenes play a role in inhibiting cellular 
viability and inducing apoptosis. This result was clear in the cytotoxicity assay and in 
the morphology of the MDA-MB-231 cells treated with different concentrations of 
chromenes. Apoptosis was further confirmed by PARP cleavage expression which was 
detected by Western blot.  
       Furthermore, cell cycle represents another target in developing chemotherapy 
against cancer cells [36]. Interestingly, our results showed that C15 induced cell cycle 
arrest at G2/M phase and more precisely at the M phase. This result was further 
supported by Western blotting analysis of specific marker to mitotic arrest which 
revealed an increased level of H3-phospho (Ser10). Interestingly, we found that cell 
cycle arrest correlated with an upregulation of the CDK inhibitor p21. Indeed, p21 is 
known to block cell cycle by binding to CDK and thus inhibiting its activity. Several 
studies suggested a pro-apoptotic role for p21. Indeed, it was revealed that apoptosis 
coexisted with induction of p21 without defining whether p21 is needed for the 
induction of apoptosis [37].  Hence, we cannot rule out a potential involvement of p21 
in the induction of apoptosis in response to chromenes. 
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      Since microtubules play a critical role in mitosis by creating the mitotic spindle, 
tubulin has long been a natural target for chemotherapeutics [38]. The most commonly 
prescribed successful anticancer therapies, that target microtubules are Paclitaxel and 
Docetaxel. These two chemotherapy agents play a role in Taxane  binding site which 
serve  as one of the major classes of microtubule-interacting agents [39,40] . The other 
two classes are Vinca and Colchicine site binders. Vincristine and Vinblastine are 
clinically applied microtubule-interacting agents that bind with Vinca alkaloid site [41] 
. The widespread clinical use of these agents in a variety of cancers reveal the 
importance of tubulin and its role in cancer.  Interestingly, in our study, we showed 
that chromenes induces targeted breast cancer cells through induction of mitotic block 
with subsequent activation of the apoptotic pathway. We also showed that mitotic 
block is not a consequence of genotoxic effect of the chromenes as no significant DNA 
damage was detected  in treated-cells. Hence we can speculate that chromenes might 
induce mitotic block through targeting the assembly of the mitotic spindle or inducing 
microtubule depolymerization, possibly by targeting the tubulin. Further investigation 
to examine this hypothesis is underway in the lab. 
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Chapter 5: Conclusion 
 
         In conclusion, in this study we showed that the newly designed chromenes affect 
significantly inhibited cellular viability of TNBC in a concentration- and time-
dependent manner. Moreover, chromenes induced cell cycle arrest and apoptosis and 
upregulated the CDK inhibitor p21. Results from this study provide  preliminary 
evidence that chromenes possesses a potential anti-cancer activity against the most 
aggressive and invasive form of breast cancer and therefore deserves more attention 
for further investigations to study the mechanism(s) of action of these compounds. 
27 
 
 
 
 
Bibliography 
 
1. Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. 
(2011). Global cancer statistics. CA: a cancer journal for clinicians, 61(2), 
69-90. 
2. Kumar, R., Chaudhary, K., Gupta, S., Singh, H., Kumar, S., Gautam, A., ... & 
Raghava, G. P. (2013). CancerDR: cancer drug resistance database. Scientific 
reports, 3. 
3. Banerjee, A., Dahiya, M., Anand, M. T., & Kumar, S. (2013). Inhibition of 
Proliferation of Cervical and Leukemic Cancer Cells by Penicillin G. Asian 
Pacific Journal of Cancer Prevention, 14(1), 2127-2130. 
4. Anand, P., Kunnumakara, A. B., Sundaram, C., Harikumar, K. B., Tharakan, 
S. T., Lai, O. S., ... & Aggarwal, B. B. (2008). Cancer is a preventable disease 
that requires major lifestyle changes. Pharmaceutical research, 25(9), 2097-
2116. 
5. Dubai Health Authority. Dubai Health Care Provision Report 2008. 
6. Maxwell, K. N., & Nathanson, K. L. (2013). Common breast cancer risk 
variants in the post-COGS era: a comprehensive review. Breast Cancer Res, 
15(6), 212. 
7. Eccles, S. A., Aboagye, E. O., Ali, S., Anderson, A. S., Armes, J., 
Berditchevski, F., ... & Bundred, N. J. (2013). Critical research gaps and 
translational priorities for the successful prevention and treatment of breast 
cancer. Breast Cancer Research, 15(5), R92. 
8. Tate, C. R., Rhodes, L. V., Segar, H. C., Driver, J. L., Pounder, F. N., Burow, 
M. E., & Collins-Burow, B. M. (2012). Targeting triple-negative breast 
28 
 
 
 
 
cancer cells with the histone deacetylase inhibitor panobinostat. Breast 
Cancer Res, 14(3), R79. 
9. Li, C. I. (Ed.). (2010). Breast cancer epidemiology (pp. 204-208). New York: 
Springer.  
10. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next 
generation. cell, 144(5), 646-674. 
11. Alberts.et al, molecular biology of the cell, fifth edition 
12. Diana Piheiro, Claudio Sunkel. Mechanisms of cell cycle control. 
CanalBQ_n9.2012 
13. Egeblad M, Nakasone ES, werb Z. Tumors Organs: Complex Tissues that 
interface with the entire organism. Developmental cell (internet). 2010 Jun 15 
[ cited 2015 Aug 23]; 18(6): 884-901. Available from: 
http://www.sciencedirect.com/science/pii/51534580710002480 
14. Nigg, E. A. (2001). Mitotic kinases as regulators of cell division and its 
checkpoints. Nature reviews Molecular cell biology, 2(1), 21-32. 
 
15. Shackelford, R. E., Kaufmann, W. K., & Paules, R. S. (1999). Cell cycle 
control, checkpoint mechanisms, and genotoxic stress. Environmental health 
perspectives, 107(Suppl 1), 5. 
16. Gabrielli, B., Brooks, K., & Pavey, S. (2012). Defective cell cycle 
checkpoints as targets for anti-cancer therapies. Frontiers in pharmacology, 
3. 
17. Roos, W. P., & Kaina, B. (2012). DNA damage-induced apoptosis: From 
specific DNA lesions to the DNA damage response and apoptosis. Cancer 
Lett. 
29 
 
 
 
 
18. Vermeulen, K., Van Bockstaele, D. R., & Berneman, Z. N. (2003). The cell 
cycle: a review of regulation, deregulation and therapeutic targets in cancer. 
Cell proliferation, 36(3), 131-149. 
19. Malumbres M, Barbacid M. Mammalian cycle-dependent Kinases. Trends 
Biochem sci. 2005 Nov; 30(11): 630-41. 
20. Boutros, R., Lobjois, V., & Ducommun, B. (2007). CDC25 phosphatases in 
cancer cells: key players? Good targets?. Nature Reviews Cancer, 7(7), 495-
507. 
21. Malumbres, M., & Barbacid, M. (2009). Cell cycle, CDKs and cancer: a 
changing paradigm. Nature Reviews Cancer, 9(3), 153-166. 
22. Wong, R. S. (2011). Apoptosis in cancer: from pathogenesis to treatment. J 
Exp Clin Cancer Res, 30(1), 87. 
23. Boatright KM, Salvesen GS. Mechanisms of activation. Curr Opin Cell  
Biol.2003 
24. Pop, C., Timmer, J., Sperandio, S., & Salvesen, G. S. (2006). The 
apoptosome activates caspase-9 by dimerization. Molecular cell, 22(2), 269-
275. [cited 2015 Aug 23];.Available from: 
http://www.cell.com/article/51097276506001730/abstract 
25. Fulda, S., & Debatin, K. M. (2006). Extrinsic versus intrinsic apoptosis 
pathways in anticancer chemotherapy. Oncogene, 25(34), 4798-4811. 
26. Fulda, S. (2010). Evasion of apoptosis as a cellular stress response in cancer. 
International journal of cell biology, 2010. [internet]. 2010 Feb 18 [cited 
2015 Aug 23]. Available from: 
http://www.hindawi.com/journals/ijcb/2010/370835/abs/. 
30 
 
 
 
 
27. Vikhanskaya, F., Lee, M. K., Mazzoletti, M., Broggini, M., & Sabapathy, K. 
(2007). Cancer-derived p53 mutants suppress p53-target gene expression—
potential mechanism for gain of function of mutant p53. Nucleic acids 
research, 35(6), 2093-2104. 
28. Elmore S. (2007) Apoptosis: A Review of Programmed Cell Death . 
Toxicologic  Pathology  ];35(4):495-516. [internet]. 2007 [cited 2016 Jan 21] 
Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2117903/ 
29. Igney, F. H., & Krammer, P. H. (2002). Death and anti-death: tumour 
resistance to apoptosis. Nature Reviews Cancer, 2(4), 277-288. 
30. Patil, S. A., Patil, R., Pfeffer, L. M., & Miller, D. D. (2013). Chromenes: 
potential new chemotherapeutic agents for cancer. Future medicinal 
chemistry, 5(14), 1647-1660. 
31. Grad, J. M., Cepero, E., & Boise, L. H. (2001). Mitochondria as targets for 
established and novel anti-cancer agents. Drug Resistance Updates, 4(2), 85-
91. 
32. Los, M., Burek, C. J., Stroh, C., Benedyk, K., Hug, H., & Mackiewicz, A. 
(2003). Anticancer drugs of tomorrow: apoptotic pathways as targets for drug 
design. Drug discovery today, 8(2), 67-77. 
33. Cai, S. X., Drewe, J., & Kemnitzer, W. (2009). Discovery of 4-aryl-4H-
chromenes as potent apoptosis inducers using a cell-and caspase-based Anti-
cancer Screening Apoptosis Program (ASAP): SAR studies and the 
identification of novel vascular disrupting agents. Anti-Cancer Agents in 
Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer 
Agents), 9(4), 437-456. 
 
31 
 
 
 
 
34. Kemnitzer, W., Jiang, S., Zhang, H., Kasibhatla, S., Crogan-Grundy, C., 
Blais, C., ... & Tseng, B. (2008). Discovery of 4-aryl-2-oxo-2H-chromenes as 
a new series of apoptosis inducers using a cell-and caspase-based high-
throughput screening assay. Bioorganic & medicinal chemistry letters, 
18(20), 5571-5575. 
35. Shestopalov, A. M., Litvinov, Y. M., Rodinovskaya, L. A., Malyshev, O. R., 
Semenova, M. N., & Semenov, V. V. (2012). Polyalkoxy Substituted 4 H-
Chromenes: Synthesis by Domino Reaction and Anticancer Activity. ACS 
combinatorial science, 14(8), 484-490. 
36. McDonald, E. R., & El-Deiry, W. S. (2000). Cell cycle control as a basis for 
cancer drug development (Review). International journal of oncology, 16(5), 
871-957. [internet]. 2000 May 1 [cited 2016 Jan 18]; Available from: 
http://www.spandidos-publications.com/ijo/16/5/871 
37. Abbas, T., & Dutta, A. (2009). p21 in cancer: intricate networks and multiple 
activities. Nature Reviews. Cancer, 9(6), 400–414. 
38. Jordan MA, Wilson L. (2004). Microtubules as a target for anticancer drugs. 
Nat. Rev. Cancer 4, 253–265 (2004).  
39. Jordan MA. (2002).  Mechanism of action of antitumor drugs that interact 
with microtubules and tubulin. Curr. Med. Chem. Anticancer Agents 1, 1–17. 
40. Kavallaris M. (2010).  Microtubules and resistance to tubulin-binding agents. 
Nat. Rev. Cancer 10(3), 194–204.  
32 
 
 
 
 
41. Dumontet C, Sikic BI. (1999).  Mechanisms of action of and resistance to 
antitubulin agents: microtubule dynamics, drug transport, and cell death. J. 
Clin. Oncol. 17, 1061–1070.  
 
 
 
